Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis

Author： Papp Kim  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.10, 2010-10, pp. : 2287-2300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Upregulation of tumor necrosis factor alpha‐induced protein 3 interacting protein 1 mRNA in psoriasis vulgaris

By  

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 13, Iss. 2, 2015-02 ,pp. : 159-161

John Wiley & Sons Inc

Access to resources Recommend Favorite

The risk of tuberculosis in patients with psoriasis treated with anti‐tumor necrosis factor agents

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 594-599

John Wiley & Sons Inc

Access to resources Recommend Favorite

Loss of SH3 Domain–Binding Protein 2 Function Suppresses Bone Destruction in Tumor Necrosis Factor–Driven and Collagen‐Induced Arthritis in Mice

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 656-667

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brief Report: Endothelial‐Specific X‐Box Binding Protein 1 Deficiency Limits Tumor Necrosis Factor–Induced Leukocyte Recruitment and Vasculitis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 12, 2015-12 ,pp. : 3279-3285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recalcitrant psoriatic uveitis and anti‐tumor necrosis factor‐α monoclonal antibodies: experience from a psoriasis referral center

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 9, 2015-09 ,pp. : 1105-1108

John Wiley & Sons Inc

Access to resources Recommend Favorite